Citation
Winhusen, Theresa, et al. "A Double-blind, Placebo-controlled Trial of Tiagabine for the Treatment of Cocaine Dependence." Drug and Alcohol Dependence, vol. 91, no. 2-3, 2007, pp. 141-8.
Winhusen T, Somoza E, Ciraulo DA, et al. A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence. Drug Alcohol Depend. 2007;91(2-3):141-8.
Winhusen, T., Somoza, E., Ciraulo, D. A., Harrer, J. M., Goldsmith, R. J., Grabowski, J., Coleman, F. S., Mindrum, G., Kahn, R., Osman, S., Mezinskis, J., Li, S. H., Lewis, D., Horn, P., Montgomery, M. A., & Elkashef, A. (2007). A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence. Drug and Alcohol Dependence, 91(2-3), 141-8.
Winhusen T, et al. A Double-blind, Placebo-controlled Trial of Tiagabine for the Treatment of Cocaine Dependence. Drug Alcohol Depend. 2007 Dec 1;91(2-3):141-8. PubMed PMID: 17629631.
TY - JOUR
T1 - A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence.
AU - Winhusen,Theresa,
AU - Somoza,Eugene,
AU - Ciraulo,Domenic A,
AU - Harrer,Judy M,
AU - Goldsmith,R Jeffrey,
AU - Grabowski,John,
AU - Coleman,Florence S,
AU - Mindrum,Gordon,
AU - Kahn,Roberta,
AU - Osman,Sabuhi,
AU - Mezinskis,Juris,
AU - Li,Shou-Hua,
AU - Lewis,Daniel,
AU - Horn,Paul,
AU - Montgomery,Margaret A,
AU - Elkashef,Ahmed,
Y1 - 2007/07/16/
PY - 2007/03/29/received
PY - 2007/05/16/revised
PY - 2007/05/17/accepted
PY - 2007/7/17/pubmed
PY - 2008/4/2/medline
PY - 2007/7/17/entrez
SP - 141
EP - 8
JF - Drug and alcohol dependence
JO - Drug Alcohol Depend
VL - 91
IS - 2-3
N2 - BACKGROUND: The potential efficacy of tiagabine for treating cocaine dependence is suggested by both pre-clinical research and two small clinical trials. METHOD: One hundred and forty one participants who met DSM-IV criteria for cocaine dependence were enrolled into this 12-week, double blind, placebo controlled outpatient trial. Participants received either tiagabine (20 mg/day) or matching placebo. All participants received 1h of manualized individual cognitive behavioral therapy on a weekly basis. Outcome measures included cocaine use as determined by self-report confirmed with urine benzoylecgonine (BE) results, and qualitative and quantitative urine toxicology measures. Safety measures included adverse events, EKGs, vital signs, and laboratory tests. RESULTS: Seventy-nine participants (i.e., 56%) completed the 12-week trial. The safety results suggest that tiagabine was safe and generally well tolerated by the participants. Participants in both groups improved significantly on cocaine craving and global functioning, with no significant differences between the groups. There were no significant changes in cocaine use as measured by self-report confirmed by urine BE or by quantitative urine toxicology results. Qualitative urine toxicology results suggest a possible weak effect for tiagabine in reducing cocaine use. CONCLUSION: These results suggest that tiagabine, at a dose of 20 mg/day, did not have a robust effect in decreasing cocaine use.
SN - 0376-8716
UR - https://www.unboundmedicine.com/medline/citation/17629631/A_double_blind_placebo_controlled_trial_of_tiagabine_for_the_treatment_of_cocaine_dependence_
L2 - https://linkinghub.elsevier.com/retrieve/pii/S0376-8716(07)00238-4
DB - PRIME
DP - Unbound Medicine
ER -